Roskamp Institute study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the scientific journal Amyloid. Work by Dr. Michael Mullan and Dr. Daniel Paris showed that a protein central to Alzheimer’s disease pathology is also able to prevent blood vessel growth and stop tumors. In our current study, we investigated whether shorter versions of this same protein could have the same effect. By stopping the blood supply to a tumor, we can effectively starve it and stop cancer. In this study, we have identified a small protein that is able to halt blood vessel growth. Therefore, this short protein has great potential as a novel treatment for cancer. The Roskamp Institute specializes in Alzheimer’s Disease research and under the leadership of Dr Michael Mullan has focussed on the role of inflammation in Alzheimer’s Disease and on new treatments for Alzheimer’s Disease and other disorders. The work on the potential role of Aβ on tumor vessel growth arose out of studies by Drs. Paris, Mullan and colleagues suggesting that Aβ might negatively impact blood vessel growth in Alzheimer’s Disease. In particular Drs Paris and Mullan have shown that the Alzheimer’s Aβ increases the tendency of blood vessels to constrict and others have confirmed that this tendency may make the effects of stroke worse in Alzheimer’s Disease patients.
Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide (2008). Patel N, Quadros A, Brem S, Wotoczek-Obadia M, Mathura V, Laporte V, Mullan M, Paris D Amyloid 15(1):5-19.
For more information please visit: